Therapeutic potential of splice-switching oligonucleotides.
about
A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophyB Cell Receptor Activation Predominantly Regulates AKT-mTORC1/2 Substrates Functionally Related to RNA ProcessingSynthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicingSilencing disease genes in the laboratory and the clinicLong-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.Enhancement of β-Globin Gene Expression in Thalassemic IVS2-654 Induced Pluripotent Stem Cell-Derived Erythroid Cells by Modified U7 snRNA.An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicingImproved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.Anti-tumor activity of splice-switching oligonucleotides.Flavin conjugates for delivery of peptide nucleic acids.Efficient in vivo manipulation of alternative pre-mRNA splicing events using antisense morpholinos in mice.Human slow troponin T (TNNT1) pre-mRNA alternative splicing is an indicator of skeletal muscle response to resistance exercise in older adults.Antitumorigenic potential of STAT3 alternative splicing modulationExpanding the action of duplex RNAs into the nucleus: redirecting alternative splicing.Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression.Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicingTuning of alternative splicing--switch from proto-oncogene to tumor suppressorU1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In VivoEnhanced splice correction by 3', 5'-serinol and 2'-(ω-O-methylserinol) guarded OMe-RNA/DNA mixmers in cellsEmerging role of alternative splicing of CRF1 receptor in CRF signaling.Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.Perspectives on gene therapy in myotonic dystrophy type 1.Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.Oligonucleotide conjugates for therapeutic applications.Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.Self-antigen expression in the peripheral immune system: roles in self-tolerance and type 1 diabetes pathogenesis.Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.A high-throughput screening assay for the functional delivery of splice-switching oligonucleotides in human melanoma cells.Direct oligonucleotide-photosensitizer conjugates for photochemical delivery of antisense oligonucleotides.Nuclease resistant oligonucleotides with cell penetrating properties.Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based TherapeuticsModulation of RNA splicing as a potential treatment for cancer.Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery.Dendrimer Conjugates for Light-activated Delivery of Antisense Oligonucleotides.Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene.Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells.PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation.
P2860
Q28244480-8BF5ED16-53E4-44E2-A47B-BAE883339BB4Q28553375-EC25DC61-090C-4138-A8EE-75F5FA34F650Q28830393-F5010B93-FB65-4A7D-A97D-C38E9EF0589BQ29039090-198B965A-EE1E-4C36-8AA5-A6BF8893176CQ33573648-421DFE93-3D5C-4EDF-B630-4E100C2AAAECQ33722582-5ECEA076-CFF6-427C-9070-F0E733C3F6ABQ33867447-E46892C0-6FD8-4504-A009-7E7E44EECB87Q34367048-0258BA92-CCD1-4CA6-A16F-22883643A60AQ34401490-72E67AB7-F1D9-4C26-A031-E683F17720A6Q34468029-ACD49995-9DFB-4C49-93EC-0D3C3FAE003EQ34675818-966489FF-EF64-4370-A9CF-D85D74B27631Q34974513-EE1E3E88-59A9-4745-8E19-5EF97CCCCD72Q35471200-5482D3E4-A035-4E54-9E8F-AE1052D96303Q35740521-E1ECA683-F5B7-4261-861F-0118744A6215Q35867143-76E923A4-3B71-4546-9CE4-027C9505AA48Q36004826-7E2A3A63-B092-4608-8B9D-CB71FD84A0D2Q36503982-678AB2CB-FA43-4D33-81E6-4E6431E66B97Q36757152-984CDA8F-7BE9-4ABD-A8E5-89A5D3886845Q37655781-DF4DEA65-F99F-4712-90AE-9C2745929DFFQ37710423-43F9C604-BB2D-4DB7-938F-10D4ACFECC8BQ37734660-3622F17F-76DF-4119-A64C-341EE71AB3FFQ37831858-C6E51698-E061-471F-8ED1-2C10762FF207Q37850458-37545FF9-841F-47B3-87AF-4255B485EF92Q38123854-8EDA1596-3E52-4D73-A17B-8D41534A39E3Q38200560-A9B30B91-F0CD-441A-B1EC-0438A6F76077Q38230215-710D0E8A-B500-4850-B7B6-FDFE5D259D30Q38300047-927598DE-B1D9-4777-BC4E-A5CDEE5B945CQ38324414-04639442-D2F6-4274-9E36-ADF33E8F5A5DQ38637311-A07A8F93-BB9A-41EA-981D-65287B39590CQ38735423-8BD335C0-BA07-48F7-BADE-7BF23EBC1360Q38884283-7FE0B21E-4379-4858-8E7B-0174D79F9549Q38898015-F9E4ED57-7943-4942-B1AC-56C6533AFF8CQ38911554-5121685C-DCF8-4323-8697-FC68230F2263Q39145734-742B9263-45C8-4B84-BBC7-A899348EDC01Q39427653-C5F7B13D-AD4B-4C36-A2C3-63788A81293AQ41490579-D93F3DCF-19E4-4418-8B89-725C97589027Q41573307-159290A6-99FA-4430-8DAA-E5F7880A7334Q42177295-6BE4A04C-57B6-42F8-96C4-5CABF047ABCFQ42189992-B047A198-BD10-4D8A-B215-C7E4D33481B7Q42787946-BFD575BC-A7DD-420F-8089-DCE2C1AF0D6C
P2860
Therapeutic potential of splice-switching oligonucleotides.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic potential of splice-switching oligonucleotides.
@en
Therapeutic potential of splice-switching oligonucleotides.
@nl
type
label
Therapeutic potential of splice-switching oligonucleotides.
@en
Therapeutic potential of splice-switching oligonucleotides.
@nl
prefLabel
Therapeutic potential of splice-switching oligonucleotides.
@en
Therapeutic potential of splice-switching oligonucleotides.
@nl
P2860
P356
P1433
P1476
Therapeutic potential of splice-switching oligonucleotides.
@en
P2093
John Bauman
Natee Jearawiriyapaisarn
P2860
P356
10.1089/OLI.2008.0161
P50
P577
2009-03-01T00:00:00Z